In the fight against emerging coronavirus variants, the need for long-lasting immunity is greater than ever… which is why the field is looking beyond antibodies and turning to T cells.
The Cell-Mediated Therapies for Infectious Disease Summit is the first industry-dedicated meeting to understand and stimulate the immune cell response to develop long term immune memory to infectious disease pathogens. See more – https://ter.li/bo7qq7
Join over 80 industry and academic leaders pioneering this new paradigm of research, and for the first time discuss novel advances in t-cell epitope-directed vaccines, as well as CAR-T, TCR and NK cell therapies designed to provoke durable immunity.
With strategic insight and clinical advances shared from Gilead, Merck, Vaccibody, TScan Therapeutics and more, join the discussion to assess:
- Bioinformatic tools to identify immunogenic targets
- Vaccine design and delivery to trigger strong T cell responses
- Bridge the gap from translatable preclinical models to IND approval
Leave this meeting with a greater understanding of next-generation approaches to target, prevent and cure HIV, EBV and SARS-CoV-2 infection.
See more – https://ter.li/bo7qq7